Four recombinant, diagnostically useful Epstein-Barr virus (EBV) proteins representative of the viral capsid antigen (pl5O), diffuse early antigen (p54), the major DNA-binding protein (pl38), and the EBV nuclear antigen (p72) The syndrome infectious mononucleosis (IM) comprises mainly fever, pharingitis, and cervical lymphadenopathy but may be complicated by splenomegaly, hepatitis, and myalgia, as well as headache and further unspecific symptoms (2). The causative agent of IM is Epstein-Barr Virus (EBV); however, other pathogens, mainly cytomegalovirus but also adenovirus, rubella virus, human immunodeficiency virus, and Toxoplasma gondii, can cause a similar syndrome. At present, testing for heterophil antibodies is frequently used to relate IM to EBV infection. These so-called Paul-Bunnell tests are simple and rapid; yet, the test results are not necessarily conclusive, because heterophil antibodies can also be induced by viruses other than EBV and because their incidence among patients with IM is, at most, 90% (3). In particular, young children (<4 years old) often lack a heterophil antibody response (22).
The syndrome infectious mononucleosis (IM) comprises mainly fever, pharingitis, and cervical lymphadenopathy but may be complicated by splenomegaly, hepatitis, and myalgia, as well as headache and further unspecific symptoms (2). The causative agent of IM is Epstein-Barr Virus (EBV); however, other pathogens, mainly cytomegalovirus but also adenovirus, rubella virus, human immunodeficiency virus, and Toxoplasma gondii, can cause a similar syndrome. At present, testing for heterophil antibodies is frequently used to relate IM to EBV infection. These so-called Paul-Bunnell tests are simple and rapid; yet, the test results are not necessarily conclusive, because heterophil antibodies can also be induced by viruses other than EBV and because their incidence among patients with IM is, at most, 90% (3) . In particular, young children (<4 years old) often lack a heterophil antibody response (22) .
The uncertainties of the Paul-Bunnell reaction can be overcome by specific EBV serodiagnosis (10) . To date this is predominantly performed by indirect immunofluorescence (IF) or immunoperoxidase (IP) staining of EBV-infected cells. Standard assays make use of fixed cells derived from selected EBV-infected cell cultures which specifically ex- press EBV-associated antigens such as the viral capsid antigens (VCAs), a set of early antigens (EAs, which can be subdivided into EA diffuse and EA restricted), and EBV nuclear antigens (EBNAs); these antigens correspond to the late lytic phase, the early lytic phase, and the phase of * Corresponding author. t Present address: Institute for Clinical Microbiology and Immunology, Frohbergstrasse 3, CH-9000 St. Gallen, Switzerland. latency of EBV infections, respectively. Qualitative and quantitative determinations of immunoglobulin M (IgM) and/or IgG antibodies against individual antigens or combinations of these antigens then allows discrimination among primary, past, and reactivated EBV infections. However, IF assays are time-consuming and are not suitable for largescale testing, and because of variability of antigen-producing cells as weil as subjective reading of results, they are also difficult to standardize.
Various attempts have been made to facilitate the specific serodiagnosis of EBV infections by developing microdilution plate assays based either on native antigens purified from EBV-infected cells (19) or on synthetic peptides selected empirically or by computer analysis from the amino acid sequences of presumptively relevant EBV-associated antigens (4, 5, 16) . The complexity of the phase-specific antigens, as well as the lack of suitable culture systems for bulk production, however, do not support their use for routine diagnosis.
By using recombinant DNA technology, defined EBVspecific antigens can be produced in sufficient amounts. Recently, suitable EBV polypeptides were selected by computer-assisted predictions of putative immunogenic regions as well as by immunoprecipitation and Western immunoblot experiments with defined EBV sera (18, 24) . The antigens were cloned, expressed in Escherichia coli, and purified to apparent homogeneity (11) . These recombinant proteins showed excellent reactivities when they were included in Western blots or enzyme-linked immunosorbent assays (ELISAs) in preliminary diagnostic studies. They have now been used to set up ELISAs for the diagnosis of EBV-2305 associated diseases. In this study we showed that, in direct comparison with results obtained by standard IF assays, these recombinant EBV ELISAs provide the means for the specific, sensitive, and rapid serodiagnosis of IM or, in more general terms, of the early acute phase of EBV infection.
MATERIALS AND METHODS Sera. A total of 75 serum specimens were collected from 57 patients who presented with clinical symptoms suggestive of IM. The symptoms commonly found in these patients included fever, tonsillar enlargement, lymphadenopathy, splenomegaly andlor hepatomegaly, hepatitis, rash, and atypical blood lymphocytes. Two to four follow-up serum specimens were available from 13 of the patients. Age, sex, and the time at which the samples were collected are specified in Tables 2 and 3 . In addition, 161 serum specimens were obtained from asymptomatic, healthy blood donors (ABDs).
Standard laboratory diagnosis. Serologic diagnosis of acute EBV infection was performed by the standard methods (10, 20) routinely used in our laboratory. IgG antibodies to VCA and EA were determined by indirect IF on the basis of slides prepared from antigen-producing P3HR1 cells in our laboratory and by use of slides purchased from Gull Laboratories, Inc. (Salt Lake City, Utah), respectively. IgM antibodies to VCA were assayed by indirect IP staining on slides available from Savyon Diagnostics Ltd. (Beer Sheva, Israel). To remove unspecific reactivities as a result of the presence of rheumatoid factors and antigen-specific IgG, the sera were preadsorbed as specified by the manufacturer of the test system. Finally, antibodies against EBNA were determined by anticomplement IF (ACIF) on slides purchased from Gull Laboratories. Sera from patients with a presumptive clinical diagnosis of IM were initially tested for IgM antibodies to VCA (VAC-IgM). If the result was negative or inconclusive, a second serum specimen was requested. For the positive diagnosis of acute EBV infection, suggestive clinical symptoms must be matched by serologic parameters indicative of a current or recent acute EBV infection. These parameters consisted of a combination of the presence of VCA-IgM, the absence or presence at very low titers of antibodies to EBNA only, or the presence of IgG antibodies to VCA (VCA-IgG) and IgG antibodies to EA.
Recombinant EBV antigens. The selected EBV genomic regions were cloned and expressed in E. coli JM109 by using standard pUC vectors. All four clones expressed stable proteins without fused bacterial proteins (see Table 1 ). The recombinant antigens were produced at a preparative scale in L broth starting with a culture volume of 6 liters and inducing synthesis by treatment with 1 mM isopropyl-,3-Dthiogalactopyranoside over a period of 4 h. Cells were harvested by centrifugation; after lysis of cells with lysozyme and subsequent sonification, the antigens were purified either from the supernatant (for p54 and p72) or from the insoluble sediment (for p138 and piS0). Purification of soluble proteins consisted of fractionation with ammonium sulphate, ion-exchange chromatography, and a final gel chromatography. The insoluble protein aggregates (inclusion bodies) of p138 and plS0 were purified by differential washing and centrifugation with increasing concentrations of detergents and chaotropic reagents at different pH values.
The average yields of the apparently homogeneous antigens ranged from 8 mg (p72) to 240 mg (pl38) per preparation. Purification was monitored by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and followed by Coomassie staining or by Western blotting under standard conditions. For Western blotting, well-defined sera were used, i.e., those that were either negative or positive for the individual EBV-associated antigen, a serum specimen that recognized E. coli proteins, as well as two monoclonal antibodies directed against p54 and p138. The final purity of the recombinant polypeptides, as calculated from gels and blots, was near 100%, except for plS0, which was obtained at about 95% purity.
Western blots. Proteins were separated by discontinuous gel electrophoresis by the method of Laemmli (13) and transferred onto membranes (Immobilon; Millipore Corp., Bedford, Mass.) by using a semidry blotting technique (12) . The blocking solution contained 10 mg of bovine serum albumin per ml in phosphate-buffered saline. Blots were cut into strips (5 mm), each of which was incubated in 2.5 ml of serum diluted 1:50 in phosphate-buffered saline with 1 mg of bovine serum albumin per ml for 4 h at room temperature. This was followed by washing (four times) with 5 ml of phosphate-buffered saline supplemented with 0.1% Tween 80. Polyclonal rabbit anti-human IgG or IgM conjugated with horseradish peroxidase (Dako, Glostrup, Denmark) was used as revealing antibody (1.5 h, room temperature). Staining of strips was performed with 3,3'-diaminobenzidine. Sera from blood donors which were ELISA positive were retested by this Western blot method by using strips with 100 ng of the corresponding purified antigen. The appearance of antigen-specific bands was defined as confirmation of an antigen-specific ELISA reaction.
ELISA procedure. Polystyrene microdilution plates (96-well; Nunc) were coated with the purified antigens at the concentrations specified in Table 1 . Identical plates were used for IgG and IgM testing. Murine monoclonal antibodies, anti-human IgG (Biotest AG, Offenbach, Federal Republic of Germany) and anti-human IgM (Janssen, Beerse, Belgium), both of which were conjugated with horseradish peroxidase, served as second antibodies. Sera were diluted 1:21 and allowed to react with the antigens at 40°C for either 30 (IgG) or 60 (IgM) min. This was followed by incubation with the second antibody at 40°C for 30 min and reaction with the substrate (1,2-phenylenediamine) at room temperature for 15 min. All reagents were used in standard volumes of 100 ,ul. The optical densities (ODs) at 492 and 620 nm were measured. Sera were always assayed in duplicate; and blank, negative, as well as positive control sera were included on each plate.
To avoid false-positive results in the IgM determinations because of the presence of rheumatoid factors (8), sera were treated overnight at 2 to 8°C with a polyclonal goat antihuman IgG Fc serum.
Frequencies of antibodies in sera from patients with IM. For calculation of the positive rates of the recombinant ELISAs, only VCA-IgM-positive sera were used, i.e., the serum specimens described in Table 2 , with the exception of the serum specimen from patient 2, together with the first VCA-IgM-positive serum specimens from the serial samples listed in Table 3 . The total number of serum specimens included was 33. four recombinant EBV antigens by a diagnostic ELISA. which was present in sera from all but one patient and which Thereby, individual antigens were used for coating microgave rise to high ODs in most cases, was anti-pl38-IgM. This dilution plates in concentrations determined earlier (11) and was followed by anti-p54-IgM, which was negative in sera as specified in Table 1 . The cutoff values were set at ODn + from only three patients. The prevalence, and, hence, the 0.1, where ODn is the OD recorded by use of a control diagnostic significance of the IgM antibodies that react with human serum which proved to be negative for antibodies the recombinant piS0 protein, was considerably lower. In against all EBV-associated antigens in standard IF tests as one case (patient 5), however, from whose serum all other well as against the recombinant antigens in Western blots.
RESULTS
markers were absent, anti-p150-IgM proved to be indicative The ODs of this serum specimen varied from 0.000 to 0.051 for primary EBV infection. Finally, anti-p72-IgM evidently for IgG assays and from 0.001 to 0.116 for IgM assays with failed to contribute substantially to the diagnosis of IM. the four antigens in different series of experiments. Sera that Significance of IgG antibodies. The diagnostic significance were reactive in the range of an OD cutoff of +0.05 were of IgG antibodies against the different recombinant proteins considered equivocal.
coincided with that of IgM antibodies (Tables 2 and 3 ).
Significance of IgM antibodies. Concerning the frequency Anti-p138-IgG and anti-p54-IgG were highly prevalent, and and diagnostic significance of antibodies against individual at least one of these markers was present in serum speciantigens (markers), the data in Tables 2 and 3 indicate that mens from 32 of 34 patients. In contrast, the incidence of marker combinations as well as relative intensities differed anti-pl50-IgG was low and anti-p72-IgG was absent in 30 of considerably among patients. The most sensitive marker, 34 serum specimens from patients with confirmed IM. The (Table 3) were not yet positive by IP staining of VCA-IgM. Three of these serum samples, however (those from patients 28, 29, and 34), were clearly IgM positive with the recombinant antigens.
Comparative reactivity in sera from patients with IM and ABDs. The reactivities of the recombinant antigens with sera from a control group of 161 apparently healthy blood donors was also investigated. All positive ELISA readings were confirmed by Western blotting. Figure 1 compares the prevalence of IgM and IgG antibodies to the four recombinant EBV-encoded antigens in sera from ABDs with those in sera from the 33 patients with confirmed IM. With the exception of low ODs against p138 in only 8% of the samples, no significant IgM reactivities with the recombinant antigens were detected in the sera from ABDs. On the contrary, most sera from patients with IM contained IgM antibodies to p54, p138, and piS0 (see above). IgG antibodies to p54 and pl38 J. CLIN. MICROBIOL. were also strongly increased in sera from patients with IM. The incidence of anti-p150-IgG, however, was low and quite similar in sera from both patients with IM and ABDs. Finally, anti-p72-IgG seemed to be a useful marker for a past EBV infection, as 84% of sera from ABDs but only 9% of sera from patients with acute IM turned out to be positive for this marker. The mean absorption values in sera from ABDs were as follows: p72-IgG, 1.324; p54-, p138-, and pl50-IgG, 0.129 to 0.169; p72-, p54-, pi38-, and p150-IgM, 0.016 to 0.103.
Reactivities of sera from patients with IM negative by VCA-IgM-IP. We tested 27 serum specimens from 23 patients who presented with IM-like symptoms, but these were found to be negative for anti-VCA-IgM by standard methods (data not shown in detail). Although they were requested, second serum specimens were available for only four patients, and these sera still proved to be negative for anti-VCA-IgM. This was also confirmed by recombinant ELISA. On the other hand, 3 (9) . The strong reactivity of the p72-IgG that we observed by ELISA was in full agreement with those in earlier studies of the highly immunogenic properties of the carboxy-terminal domain of p72. On this basis, an ELISA method has been developed which proved to be 100-fold more sensitive than ACIF (17) .
A further advantage of the recombinant p72 might arise from deletion of the Gly-Ala copolymer from its amino acid sequence. This structural part of EBNA-1 was shown to react with rheumatoid antibodies as well as with autoantibodies in sera from patients with IM (21, 23) . Furthermore, it has been suggested that the Gly-Ala copolymer of EBNA-1, together with cellular proteins with similar structures, are the target for anti-rheumatoid arthritis nuclear antigen antibodies (23) . In view of the results presented in those reports, we assume that omission of the putative cross-reacting epitopes in the amino-terminal half of p72 added substantially to the specificity of our test system.
On the basis of the results of this study, the following pl38, and p50. Additional positive markers for recent or ongoing IM can be IgG antibodies to p54 and pl38. Antip72-IgG is typically negative in the early phase of EBV infections. If it is positive, however, it is a potent indicator of past exposure to the virus. Judged on this basis, the ELISA results led to a laboratory diagnosis for the individual serum specimens from patients with IM which proved to be comparable to or even better than the diagnosis we obtained by standard IF and IP EBV serology (see column labeled R in Table 2 ).
Despite their obvious discriminative diagnostic powers, the multiple individual ELISAs, in their present form, are not suited for routine laboratory diagnosis of EBV infections. In agreement with the conclusions presented above, however, it seems to be possible to reduce the number of necessary tests per serum specimen by assaying simultaneously for anti-p54-, anti-p138, and anti-pl50-IgM, by combining p54 and pl38 in a second assay for IgG antibodies, and, finally, by testing for anti-p72-IgG. When the results shown in Fig. 1 were reevaluated by using the aforementioned hypothetical combination of antigens, the data presented in Fig. 2 evolved. It is highly suggestive of the possibility that a rapid, reliable, and discriminative ELISA system can be established for the specific diagnosis of acute EBV infection and will be tested under routine conditions in the near future. 
